Wedge Capital Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $916K | Sell |
764
-81
| -10% | -$82.8K | 0.02% | 418 |
|
|
2026
Q1 | $777K | Buy |
845
+110
| +15% | +$112K | 0.01% | 456 |
|
|
2025
Q4 | $790K | Buy |
735
+137
| +23% | +$131K | 0.01% | 454 |
|
|
2025
Q3 | $456K | Sell |
598
-53
| -8% | -$39.4K | 0.01% | 487 |
|
|
2025
Q2 | $507K | Sell |
651
-87
| -12% | -$67.6K | 0.01% | 473 |
|
|
2025
Q1 | $610K | Buy |
738
+90
| +14% | +$74.9K | 0.01% | 468 |
|
|
2024
Q4 | $500K | Sell |
648
-228
| -26% | -$189K | 0.01% | 473 |
|
|
2024
Q3 | $776K | Buy |
876
+29
| +3% | +$26.1K | 0.01% | 439 |
|
|
2024
Q2 | $767K | Sell |
847
-3
| -0.4% | -$2.4K | 0.01% | 425 |
|
|
2024
Q1 | $661K | Buy |
850
+83
| +11% | +$59.1K | 0.01% | 445 |
|
|
2023
Q4 | $447K | Sell |
767
-26
| -3% | -$15.2K | 0.01% | 450 |
|
|
2023
Q3 | $426K | Sell |
793
-652
| -45% | -$336K | 0.01% | 437 |
|
|
2023
Q2 | $678K | Sell |
1,445
-36
| -2% | -$15.1K | 0.01% | 467 |
|
|
2023
Q1 | $509K | Sell |
1,481
-4
| -0.3% | -$1.35K | 0.01% | 313 |
|
|
2022
Q4 | $543K | Buy |
1,485
+28
| +2% | +$9.93K | 0.01% | 309 |
|
|
2022
Q3 | $471K | Sell |
1,457
-61
| -4% | -$19.3K | 0.01% | 315 |
|
|
2022
Q2 | $492K | Hold |
1,518
| – | – | 0.01% | 317 |
|
|
2022
Q1 | $435K | Sell |
1,518
-72
| -5% | -$18.5K | 0.01% | 320 |
|
|
2021
Q4 | $439K | Hold |
1,590
| – | – | 0.01% | 332 |
|
|
2021
Q3 | $367K | Sell |
1,590
-17
| -1% | -$4.2K | ﹤0.01% | 335 |
|
|
2021
Q2 | $369K | Sell |
1,607
-332
| -17% | -$66.7K | ﹤0.01% | 326 |
|
|
2021
Q1 | $362K | Sell |
1,939
-285
| -13% | -$55.7K | ﹤0.01% | 413 |
|
|
2020
Q4 | $376K | Buy |
2,224
+92
| +4% | +$13.7K | ﹤0.01% | 440 |
|
|
2020
Q3 | $316K | Buy |
2,132
+133
| +7% | +$20.6K | ﹤0.01% | 436 |
|
|
2020
Q2 | $328K | Sell |
1,999
-31
| -2% | -$4.76K | ﹤0.01% | 407 |
|
|
2020
Q1 | $282K | Sell |
2,030
-73
| -3% | -$10K | ﹤0.01% | 410 |
|
|
2019
Q4 | $276K | Buy |
2,103
+13
| +0.6% | +$1.51K | ﹤0.01% | 486 |
|
|
2019
Q3 | $234K | Buy |
2,090
+68
| +3% | +$7.57K | ﹤0.01% | 520 |
|
|
2019
Q2 | $224K | Buy |
+2,022
| New | +$238K | ﹤0.01% | 578 |
|
|
2016
Q1 | – | Sell |
-460,590
| Closed | -$38.8M | – | 591 |
|
|
2015
Q4 | $38.8M | Sell |
460,590
-4,100
| -0.9% | -$340K | 0.41% | 79 |
|
|
2015
Q3 | $38.9M | Sell |
464,690
-59,925
| -11% | -$5.06M | 0.41% | 61 |
|
|
2015
Q2 | $43.8M | Sell |
524,615
-205,325
| -28% | -$15.6M | 0.42% | 75 |
|
|
2015
Q1 | $53M | Buy |
729,940
+39,215
| +6% | +$2.79M | 0.53% | 52 |
|
|
2014
Q4 | $47.7M | Buy |
690,725
+53,050
| +8% | +$3.58M | 0.48% | 76 |
|
|
2014
Q3 | $41.4M | Sell |
637,675
-160,895
| -20% | -$10.2M | 0.44% | 71 |
|
|
2014
Q2 | $49.6M | Sell |
798,570
-27,100
| -3% | -$1.62M | 0.51% | 49 |
|
|
2014
Q1 | $48.6M | Sell |
825,670
-32,200
| -4% | -$1.8M | 0.51% | 60 |
|
|
2013
Q4 | $43.8M | Buy |
857,870
+132,275
| +18% | +$6.62M | 0.46% | 80 |
|
|
2013
Q3 | $36.5M | Buy |
725,595
+53,145
| +8% | +$2.78M | 0.42% | 96 |
|
|
2013
Q2 | $33M | Buy |
+672,450
| New | +$36.6M | 0.4% | 101 |
|
Other funds holding LLY
SC
ONB
GIM
Wedge Capital Management's LLY Position: Q2 2026 in Review
Wedge Capital Management reduced its Eli Lilly (LLY) stake by 9.6% in Q2 2026, selling an estimated $82.8K and leaving 764 shares worth $916K. The position accounts for 0.02% of the portfolio, ranked #418.
Wedge Capital Management first reported a position in LLY in Q2 2013 and has held it in 40 quarters since. The position peaked at $53M in Q1 2015. 1,558 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Wedge Capital Management held 764 shares of Eli Lilly worth $916K as of Q2 2026.
- Wedge Capital Management sold 81 Eli Lilly shares in Q2 2026, an estimated $82.8K.
- Eli Lilly made up 0.02% of Wedge Capital Management's portfolio in Q2 2026, its #418 holding.
- Wedge Capital Management first reported a position in Eli Lilly in Q2 2013 and has held it in 40 quarters since.
- Wedge Capital Management's Eli Lilly position peaked at $53M in Q1 2015.
- 1,558 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Wedge Capital Management's 13F filing for Q2 2026, filed 10 Jul 2026.